A private investment group in South Carolina invests in two verticals, healthcare and advanced computing. The firm primarily invests in medical devices (60%), as well as diagnostics (20%), life science tools (10%), and AI-based drug discovery platforms (10%). The firm invests in seed-Series A, investing between $1-5M in companies that have a validated prototype and have a defined regulatory path. The firm invests primarily in US-based companies but will invest in Israel and Europe.
The firm invests primarily in medical devices, with some investments in diagnostics as well. In terms of medical devices, the firm will invest in class II and class III devices, investing either just before, during or after FDA approval for class II devices, and in devices that have received IDE approval for class III devices. For AI-based companies, the firm is interested in technologies such as drug discovery.
The firm can lead, co-invest or act as the sole investor. The firm takes a board seat with any company in which they invest. The firm will only invest in companies with validated prototypes and will not invest pre-company formation.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment